News and Events

On January 30, 2026, Elsevier officially released the 2025 "Highly Cited Chinese Researchers" list. A total of 6,310 scholars from 543 institutions were named to this prestigious list, which included scientists from only 49 enterprises across China. Among them, Dr. Chen Shifu, Founder and CTO of HaploX, has been selected for four consecutive years (2022, 2023, 2024, 2025), recognizing his extensive global influence in the fields of bioinformatics and precision oncology medicine. The list utilizes Scopus, a globally authoritative citation and indexing database, as the statistical source for Chinese scholars' research achievements, and garners significant attention from numerous media outlets and scholars worldwide.

To be included in this list, a scholar must meet the following criteria regarding their publications (as first author or corresponding author):

• Have more than one paper (i.e., at least two) indexed in Scopus.
• Have the total citations of all indexed papers reach the threshold set for their specific discipline.
• Have at least one paper that ranks in the top 1% globally by citations for its field and publication year; OR have an overall Field-Weighted Citation Impact (FWCI) greater than 1 for their papers as first/corresponding author.

Dr. Chen Shifu has been consecutively listed under the discipline of Computer Science and Technology. This sustained academic honor not only highlights his profound impact in computer science but also underscores the unique strength of HaploX as a biotech company — demonstrating robust R&D capabilities that integrate computational science, data analysis, and multidisciplinary expertise alongside solid biotechnology foundations.

Dr. Chen has long been dedicated to bioinformatics with remarkable academic influence. Since initiating the OpenGene open-source project in 2016, he has led the development of over ten widely acclaimed bioinformatics tools, including Fastp. Fastp, a sequencing data pre-processing software, is renowned for its exceptional speed and efficiency and has become a standard tool in the global bioinformatics community. The related academic paper has been cited over 20,000 times within seven years of publication, making it one of the highest-cited research papers from China in the biological sciences in recent years. The OpenGene suite has been downloaded hundreds of thousands of times, with users including prestigious international institutions such as Harvard University, the National Cancer Institute, and MIT.

As the Founder and CTO of HaploX, Dr. Chen drives technological independence and integrated innovation. He leads the team in independently developing the LIUDUS® integrated molecular diagnostics technology platform and has established a comprehensive bioinformatics software and algorithm system covering key areas like tumor NGS variant, fusion, CNV, and MSI detection, significantly enhancing testing accuracy and reliability. This marks HaploX's solid technological barrier built upon the deep integration of Biotechnology (BT) and Information Technology (IT).

Under Dr. Chen's leadership, HaploX continues to advance its tumor bioinformatics algorithms and technology R&D. Supported by the cutting-edge LIUDUS® platform, the company is achieving breakthroughs in various business domains, including whole-course tumor management, genetic disease screening, and infectious disease detection.